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Current studies evaluating the efficacy and safety of lipid-targeted therapies to reduce  
cardiovascular events are being performed on the background of statin therapy, given the 
overwhelming evidence from numerous randomized clinical studies indicating a reduction of 
occlusive vascular events by statin therapy (1).     
 
Niacin – a lipid-modifying agent with a long history:  Already in 1955 Dr Altschul and 
colleagues described that high-doses of the vitamin B 3 (niacin) reduced serum cholesterol-
levels (Figure 1)(2).  Later, the Coronary Drug Project (CDP) sponsored by the National 
Heart and Lung Institute (published in 1975) tested the efficacy and safety of long-term 
therapy with a high dose of niacin (3 g/day) in men after myocardial infarction (3).  In the 
CDP there was no significant effect of niacin therapy on the primary end point, i.e. all-cause 
mortality, but a significant reduction in the rate of recurrent non-fatal myocardial infarction 
by 27 % was observed (3).  The authors concluded that the “Coronary Drug Project data 
yield no evidence that niacin influences mortality of survivors of myocardial infarction; this 
medication may be slightly beneficial in protecting persons to some degree against recurrent 
nonfatal myocardial infarction”, that is to say that the authors were not overly enthusiastic 
with respect to the efficacy of the compound to prevent major cardiovascular events.   
Already in this early study it became apparent that the adherence to niacin therapy was 
significantly reduced as compared to placebo, likely due to the well-known skin and 
gastrointestinal side effects of the compound (3). 
 
The niacin receptor GPR109A and niacin-induced flushing: The mechanisms underlying 
the effects of niacin on lipids are still not completely understood, but include a decreased 
lipolysis due to inhibition of the hormone-sensitive triglyceride lipase in adipocytes (4).  In 
2003 the discovery of the niacin receptor, the Gi protein–coupled receptor GPR109A 
(HM74A in humans; PUMA-G in mice) was reported, that later allowed a better 
understanding of the mechanisms underlying the well-known niacin-associated flush (5).  
These studies could show that niacin-induced flushing was mediated by the niacin receptor 
GPR109A, that was also thought to mediate the effects of niacin on lipids and on 
experimental atherosclerosis (5-7).  Furthermore, it was suggested that niacin-induced 
flushing involved the release of prostaglandin D(2) and prostaglandin E(2) and the respective 
prostaglandin D(2) and prostaglandin E(2) receptors (5, 6), resulting in the concept of a 
blockade of the prostaglandin D(2) receptor-1 to reduce niacin-induced flushing.  Later, a 
clinical study in 1455 patients with dyslipidemia focusing on niacin-induced “flushing” 
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suggested that the addition of the prostaglandin D(2) receptor-1 antagonist laropiprant to 
extended-release niacin significantly reduced niacin-associated flushing (8). Moreover, 
Lukasova et al. suggested in experimental studies that niacin reduced the progression of 
atherosclerosis by direct stimulation of GPR109A on immune cells (e.g. macrophages) 
leading to reduced inflammatory activation independent of lipid-modifying effects (7).  A 
subsequent clinical study by Taylor et al. suggested that addition of extended-release niacin 
to long-term statin therapy resulted in a modest regression of carotid intima-media thickness 
in patients with coronary artery disease or risk equivalent (9).  
 
Clinical outcome trials of niacin in combination with statin therapy:  More recently two 
clinical outcome studies (AIM-HIGH and HPS2-THRIVE) have consequently been 
evaluating the effects of extended-release (ER) niacin therapy or the combination of ER-
niacin with laropiprant on cardiovascular events in addition to statin therapy (10, 11).   The 
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: 
Impact on Global Health Outcomes trial (AIM-HIGH) was aiming to evaluate the impact of 
raising HDL-cholesterol levels with niacin therapy (1.5-2 g/day) on cardiovascular events in 
subjects with similar LDL cholesterol levels (achieved by higher statin doses and ezetimibe 
therapy in the comparator treatment arm)(11).  In this study the primary end point, a 
composite of the first event of death from coronary heart disease, nonfatal myocardial 
infarction, ischemic stroke, hospitalization for an acute coronary syndrome, or symptom-
driven coronary or cerebral revascularization, was not reached by niacin therapy in patients 
with established cardiovascular disease and an atherogenic dyslipidemia (11). In fact, the trial 
was stopped early because the boundary for futility had been crossed and a higher number of 
ischemic strokes was observed in patients assigned to niacin (11).  However, the 
interpretation of the results of the trial with respect to niacin has been somewhat difficult due 
to the design, i.e. the fact that more placebo-treated patients required increases in the statin 
dose or addition of ezetimibe, that could have partly blunted a potential therapeutic benefit of 
niacin (Figure 2).   
The substantially larger Heart Protection Study 2-Treatment of HDL to Reduce the Incidence 
of Vascular Events (HPS2-THRIVE) study has now evaluated the combination of ER-niacin 
(2 g per day) with the prostaglandin D(2) receptor-1 antagonist laropiprant (40 mg) in 25,673 
patients with pre-existing occlusive vascular disease (10).  The sponsor of the trial has 
recently communicated that the study did not meet its primary endpoint of reduction of major 
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vascular events, although the detailed data presentation is still expected.  Within this large-
scale  clinical study, a careful analysis of the side effects was pre-specified, in particular with 
respect to muscle and liver outcomes and reasons for stopping study treatment that is reported 
in the current issue of the European Heart Journal.  The addition of ER-niacin/laropiprant to 
40 mg simvastatin therapy (and ezetimibe in some participants) increased the risk of definite 
myopathy.  The risk of myopathy on the combination therapy was substantially more 
pronounced in Chinese patients as compared to Europe, indicating that the safety of a drug in 
one region and in Caucasians cannot necessarily be translated to other regions, such as Asia 
(10). Interestingly, although the name of the trial focuses on the HDL-cholesterol raising 
effects of niacin, there was also a 19.9 % reduction of LDL cholesterol levels and a 19.5 % 
reduction of triglycerides already in the run-in phase and niacin is also known to lower the 
pro-atherogenic lipoprotein(a).   The vascular effects of HDL have been observed to be 
highly heterogenous, eg the endothelial-protective properties of HDL are impaired in patients 
with coronary disease or diabetes as compared to healthy subjects (12-15),  that may 
represent one mechanisms limiting beneficial effects of HDL cholesterol raising therapies in 
tehse patients.   The above observations of substantially lowered LDL cholesterol levels, 
however, raise important questions as to why niacin/laropiprant did not reduce major 
cardiovascular events.        
Cardiovascular biology of the prostaglandin D(2) receptor-1 ?  The question arises whether 
the prostaglandin D(2) receptor-1 antagonist laropiprant, that was used to reduce niacin-
induced flushing, is really biologically inert with respect to atherosclerosis and thrombosis, in 
particular since little is known about the cardiovascular biology of prostaglandin D(2).  
Interestingly, a recent experimental study has observed  that prostaglandin D(2) receptor-1 
deletion in mice augmented aneurysm formation and accelerated atherogenesis and 
thrombogenesis, and these authors suggested that niacin-induced PGD₂ release may function 
as a constraint on platelets during niacin therapy (16).  The effects of inhibition of the PG-
D(2) receptor-1 by laropiprant on thrombosis and atherosclerosis in humans in vivo are likely 
difficult to predict and complex, since it has been observed that on the one hand laropiprant at 
low concentrations prevented the inhibitory effects of PGD2 on platelet function, including 
effects on platelet aggregation and thrombus formation, but on the other hand laropiprant at 
higher concentrations attenuated platelet activation induced by thromboxane and inhibited 
thrombus formation (17).  Similarly, the effects of prostaglandin D(2) receptor-1 inhibition 
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on atherosclerotic plaque formation in mouse models have not been consistent, with 
accelerated atherosclerosis in some, but not all atherosclerotic mouse models (18).  
 
Where do we go from here ?  Given the disappointing efficacy results of the two recent 
clinical outcome studies of extended-release niacin in addition to statin therapy and the 
increased risk of myopathy observed in the HPS2-THRIVE study, niacin has failed as a 
valuable “partner” of statin therapy in lipid-targeted approaches to further reduce major 
cardiovascular events in high-risk patients.   There are, however, several large scale clinical 
trials under way that either focus on further LDL cholesterol reduction by inhibition of 
intestinal absorption (IMPROVE-IT) or PCSK9 antagonism (eg ODYSSEY), on combined 
LDL-cholesterol lowering and HDL-cholesterol raising by potent CETP inhibition with 
anacetrapib (HPS3-TIMI55) or evacetrapib (ACCELERATE) or on short-term HDL raising 
by infusion (Figure 3).    
 
At present, statin therapy has clearly shown to effectively reduce vascular events and is 
reasonably well tolerated in most patients.  We will still have to wait for the results of the 
above ongoing studies to see whether another lipid-targeted intervention can further reduce 
vascular events in addition to statin therapy.  At the same time other therapeutic strategies 
targeting mechanisms known to be involved in the progression of atherosclerotic vascular 
disease, such as anti-inflammatory therapies (low-dose methotrexate; IL-1beta antibody) (19, 
20), have been initiated to determine whether such treatment strategies can further reduce 
cardiovascular events in addition to statin therapy with an acceptable safety profile.   
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Figure legends: 
 
Figure 1:  Niacin (vitamin B3) – a lipid-modifying agent with a long history   
 
Figure 2:  Comparison of the Aim-High and the HPS2-THRIVE trial.   
 
Figure 3: Strategies of ongoing clinical trials to examine which lipid-targeted therapy should 
be added to statin treatment in patients with high vascular risk.    
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